Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.

A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.

Human NK cells engineered to express a PD-L1 chimeric antigen receptor can control murine and human tumors and reduce myeloid cells expressing high levels of PD-L1.

A new, high-throughput in vivo MHC-I peptide minigene library platform shows that the naive immune system cannot eliminate cells presenting immunogenic antigens found at low frequencies within a growing tumor.

Why does cancer develop in situations where the immune system is perfectly capable of eliminating it?

Advances in techniques for analysing single cells and tissues have inspired an international effort to create comprehensive reference maps of all human cells - the fundamental units of life - as a basis for both understanding human health and diagnosing, monitoring and treating disease.

We identify key strengths and limitations in use of viral genotyping and phenotyping to estimate pandemic risk from influenza A viruses, focusing on 3 traits, hemagglutinin binding specificity, hemagglutinin pH of activation, and polymerase complex efficiency.

Discussions about biological individuality and immunogenicity continue the long history of dialogue between philosophers and immunologists.

Osteoclasts emerging in inflammation are heterogeneous and encompass a strongly inflammatory subset with a high resorbing activity and an immune suppressive subset that are able to control each other.

Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.